Matthew S. Davids, MD, MMSc, discusses the current treatment landscape for patients with chronic lymphocytic leukemia beyond chemoimmunotherapy.
Matthew S. Davids, MD, MMSc, director of clinical research in the Lymphoma Program and a medical oncologist at Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School, discusses the current treatment landscape for patients with chronic lymphocytic leukemia (CLL) beyond chemoimmunotherapy.
According to Davids, a number of novel agents have been approved by the FDA for the treatment of patients in the frontline setting, which is beginning to replace the role of chemoimmunotherapy in this space. The most widely used treatment for frontline CLL has become ibrutinib (Imbruvica), which is a Bruton’s kinase (BTK) inhibitor.
The second BTK inhibitor, acalabrutinib (Calquence) received its approval for the frontline treatment of patients with CLL. Both BTK inhibitors are continuous therapy regimens, but the combination of venetoclax (Venclexta) plus obinutuzumab (Gazyva) is now challenging this approach as a time-limited therapy regimen to replace chemoimmunotherapy.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More